X

Trial Profile

A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Repotrectinib (Primary) ; Trametinib (Primary)
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms TRIDENT-2
Sponsors Turning Point Therapeutics

Most Recent Events

13 Apr 2023 Status changed from active, no longer recruiting to discontinued.
07 Nov 2022 Status changed from recruiting to active, no longer recruiting.
08 Apr 2022 Results assessing malignancy suspicious-Noninvasive Prenatal Test cases using patients from this study published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com